The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Disc Medicine; Galecto; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Keros Therapeutics; Merck; MorphoSys; MorphoSys; Novartis; Pharmaessentia; Roche/Genentech; SOBI; Sumitomo Pharma Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); Disc Medicine; Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); MorphoSys; Novartis (Inst); Pharmaessentia (Inst); SOBI
 
Terrence Bradley
Consulting or Advisory Role - Geron; Gilead Sciences; Novartis
Speakers' Bureau - Novartis
 
Bart Scott
Honoraria - Alexion Pharmaceuticals; Alexion Pharmaceuticals; Bristol-Myers Squibb; Incyte; Novartis; Taiho Oncology
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Celgene; Novartis
Speakers' Bureau - Alexion Pharmaceuticals; Celgene; Jazz Pharmaceuticals; Novartis
Research Funding - Celgene (Inst)
 
Habte Yimer
Employment - Texas Oncology/US Oncology
Stock and Other Ownership Interests - Karyopharm Therapeutics
Speakers' Bureau - Abbvie; Amgen; BeiGene; G1 Therapeutics; Genmab; Janssen; Karyopharm Therapeutics; Pfizer
 
Souria Dougherty
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Lixian Peng
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Fei Huang
Employment - Geron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Geron; Johnson & Johnson
 
Ying Wan
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Faye Feller
Employment - Geron
Stock and Other Ownership Interests - Geron
Travel, Accommodations, Expenses - Geron
 
Vivian Rodolf
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Judy Ho
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Tymara Berry
Employment - Geron
Stock and Other Ownership Interests - Geron
 
Andrew Kuykendall
Honoraria - Abbvie/Genentech; Blueprint Medicines; BMS; GlaxoSmithKline; Incyte; MorphoSys; Opna Bio; Pharmaessentia; SOBI
Consulting or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; Karyopharm Therapeutics; Keros Therapeutics; MorphoSys; Protagonist Therapeutics
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Geron (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Inst); MorphoSys (Inst); Novartis (Inst); Protagonist Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Pharmaessentia; Protagonist Therapeutics
 
Salman Otoukesh
No Relationships to Disclose